Forecasts data is unavailable for this security.
Consensus recommendation
- 20-Feb-25
- 20-Nov-25
- 18-Dec-25
- 15-Jan-26
- 26-Feb-26
Select bar for recommendation details.
| Recommendations | 26-Feb-26 | |
|---|---|---|
| Buy | 4 | |
| Outperform | 6 | |
| Hold | 1 | |
| Sell | 1 | |
| Strong Sell | 0 |
Share price forecast in USD
The 10 analysts offering 12 month price targets for Hikma Pharmaceuticals Plc have a median target of 2,199.41, with a high estimate of 2,648.78 and a low estimate of 1,599.50. The median estimate represents a 67.38% increase from the last price of 1,314.00.
| High | 101.6% | 2,648.78 |
| Med | 67.4% | 2,199.41 |
| Low | 21.7% | 1,599.50 |
Dividends in USD
In 2025, Hikma Pharmaceuticals PLC reported a dividend of 0.48 USD, which represents a 37.59% decrease from last year. The 12 analysts covering the company expect dividends of 0.86 USD for the upcoming fiscal year, an increase of 79.79%.
Note: The percentage change is calculated using unrounded (raw) dividend values.
| Div growth (TTM) | -37.59% |
|---|
More ▼
Earnings history & estimates in USD
| Average growth rate | +7.23% |
More ▼
Revenue history & estimates in USD
| Average growth rate | +7.17% |
More ▼
